Trials & Filings

Vivus Receives Qysmia Patents

New patents extend weight-loss drug coverage to 2029

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

The U.S. Patent and Trademark Office has issued to Vivus Patent Nos. 8,580,298 (link: 8580298; ‘298), covering compositions of Qsymia, and 8,580,299 (link: 8580299; ‘299), covering methods for effecting weight loss using Qsymia. The newly issued patents are assigned to Vivus and are a significant addition to the existing foundational patents, listed in the FDA Orange Book, that provide market exclusivity for Qsymia. Prior to issuance of these new patents, patent protection for Qsymi...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters